125 related articles for article (PubMed ID: 8731722)
1. Fibrate monotherapy and profound hypoalphalipoproteinaemia.
Olukoga AO; Crowley VE; Stewart MF; Weinkove O
Postgrad Med J; 1996 Mar; 72(845):189. PubMed ID: 8731722
[No Abstract] [Full Text] [Related]
2. Ciprofibrate and lipid profile.
McLeod AJ; Warren RJ; Armitage M
Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
[No Abstract] [Full Text] [Related]
3. Fibrates and HDL cholesterol.
Murphy MJ; Packard CJ; O'Reilly DS
Ann Clin Biochem; 1997 Jan; 34 ( Pt 1)():114. PubMed ID: 9022900
[No Abstract] [Full Text] [Related]
4. Abnormal lipid profiles on fibrate derivatives.
McLeod AJ; Warren RJ; Armitage M
Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
[No Abstract] [Full Text] [Related]
5. Fibrate treatment can increase serum creatinine levels.
Tsimihodimos V; Kakafika A; Elisaf M
Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
[No Abstract] [Full Text] [Related]
6. Creatinine rise after fibrate therapy in renal graft recipients.
Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C
Lancet; 1993 Mar; 341(8848):840. PubMed ID: 8096050
[No Abstract] [Full Text] [Related]
7. Fibrate-induced increase in blood urea and creatinine.
Lipscombe J; Bargman JM
Nephrol Dial Transplant; 2001 Jul; 16(7):1515. PubMed ID: 11427661
[No Abstract] [Full Text] [Related]
8. [Myositis, hypothyroidism and fibrates].
Wechsler B; Doumith R; Weil M
Rev Med Interne; 1991; 12(6):475. PubMed ID: 1792441
[No Abstract] [Full Text] [Related]
9. Fibrates and renal function.
Gajdos M; Dzúrik R
Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
[No Abstract] [Full Text] [Related]
10. [Ciprofibrate-induced acute cholestatic hepatitis].
Pflumio F; Andrès E; Ubrich M; Geisler F; Imbs JL; Di Liberatore M
Ann Endocrinol (Paris); 2003 Jun; 64(3):232-3. PubMed ID: 12910067
[No Abstract] [Full Text] [Related]
11. [Does hypothyroidism predispose muscular toxicity of fibrates?].
Tregouet B
Rev Med Interne; 1991; 12(2):159. PubMed ID: 1853004
[No Abstract] [Full Text] [Related]
12. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
[No Abstract] [Full Text] [Related]
13. [Acute severe fibrosing hepatitis associated with ciprofibrate treatment].
Dumortier J; Slim R; Chevallier M; Boillot O; Thaunat JL; Vaillant E; Vial T; Bellemin B; Paliard P; Scoazec JY
Gastroenterol Clin Biol; 1999 Dec; 23(12):1399-400. PubMed ID: 10642628
[No Abstract] [Full Text] [Related]
14. [Acute rhabdomyolysis during treatment with ciprofibrate].
Delangre T; Vernier L; Moore N; Mihout B
Presse Med; 1990 Nov; 19(39):1811-2. PubMed ID: 2148009
[No Abstract] [Full Text] [Related]
15. Lipid profiles on fibric-acid derivatives.
Capps NE
Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
[No Abstract] [Full Text] [Related]
16. [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].
Blain H; Klein M; Weryha G; Tréchot P; Hanesse B; Leclère J
Rev Med Interne; 1996; 17(10):859-60. PubMed ID: 8976986
[No Abstract] [Full Text] [Related]
17. [Cytolytic hepatic damage caused by ciprofibrate].
Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
[No Abstract] [Full Text] [Related]
18. Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
Legras B; Clerc C; Ruelland A; Doualin G; Fertil V; Cloarec L
Clin Chem; 1990 Mar; 36(3):580-1. PubMed ID: 2107044
[No Abstract] [Full Text] [Related]
19. Ciprofibrate and lipid profile.
Chandler HA; Batchelor AJ
Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
[No Abstract] [Full Text] [Related]
20. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
Ramachandran S; Giles PD; Hartland A
BMJ; 1997 May; 314(7094):1593. PubMed ID: 9186171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
